Charter Communications shares surged Friday after the cable giant reported a rare quarterly gain in pay-TV subscribers, a bright spot amid ongoing broadband pressures. The company's strategy of bundling streaming services appears to be resonating with customers.
Damascus residents face electricity bills exceeding their monthly incomes after a massive government price hike, sparking rare public protests and deepening the crisis for a war-weary population.
From economic despair to demands for fundamental rights, Iran's recent wave of protests revealed a rare, broad-based defiance. Through the eyes of those who were there, a story emerges of fleeting hope shattered by a security response activists call the deadliest in decades.
SpaceX is reportedly targeting June 2026 for its long-awaited public market debut, with sources suggesting the timing could be synchronized with a rare planetary alignment and CEO Elon Musk's 55th birthday, as the company seeks capital for its ambitious Mars missions.
Former Iranian President Hassan Rouhani has issued a stark warning to the regime, urging sweeping reforms to address public grievances as internal divisions surface following a deadly crackdown on protests. The rare public criticism from within the establishment highlights growing tensions ahead of renewed nuclear talks.
In a rare show of unity, Pennsylvania's political leaders from both parties are rallying behind the state's famed weather-predicting groundhog, pushing back against an animal rights group's call to replace the living animal with a digital projection.
The enterprise software firm's unprecedented Bitcoin treasury position fell below its average cost basis over the weekend, marking a rare paper loss event, even as the company continues its aggressive acquisition strategy.
After years of share price weakness, Immunocore Holdings (IMCR) appears significantly undervalued by traditional metrics. But does the market know something the models don't? We examine the DCF and P/S analyses, the company's unique T-cell receptor platform, and the risks that have kept investors wary.
From delivering pizzas to building a global sportswear empire, Ben Francis's journey to a $1.4 billion net worth is a modern business fable. Yet, in a candid podcast interview, the Gymshark CEO argues that equating self-worth with wealth is a 'wildly unproductive way to live,' offering a rare glimpse into the mindset behind the paper fortune.
Wells Fargo boosts its price target for Taysha Gene Therapies (TSHA), citing strong progress in its pivotal Rett syndrome gene therapy program. The company has dosed the first patient in a key trial phase and received FDA alignment on its regulatory pathway.
The Apis Flagship Fund reported robust quarterly and annual gains for 2025, significantly beating global benchmarks. While highlighting its performance drivers, the fund's investor letter also discussed its position on gene therapy firm uniQure (QURE).
MarketAxess Holdings (MKTX), once a high-flying fintech darling, has seen its share price erode by nearly 70% over five years. As the bond trading platform grapples with shifting market dynamics and increased competition, investors are left debating whether the current valuation presents a rare buying opportunity or signals deeper structural challenges.
Digital asset funds have recorded a second consecutive week of massive outflows, totaling $1.7 billion, as hawkish Fed signals and geopolitical tensions trigger a defensive shift. While Bitcoin and Ethereum led the retreat, tokenized precious metals emerged as a rare destination for new capital.
Shares of specialty insurer Kinsale Capital have tumbled over 11% in six months, starkly underperforming the surging S&P 500. As investors digest its latest earnings, the debate intensifies: Is this a rare chance to buy a high-growth company at a discount, or a signal of deeper challenges ahead?
In a rare break from Wall Street's typically optimistic consensus, a handful of prominent stocks are receiving bearish price targets that signal deep-seated concerns. We examine the challenges facing Deckers, MSC Industrial, and Guardant Health, and why investors might want to look elsewhere.
Takeda Pharmaceutical raises its FY2025 revenue and profit guidance following resilient nine-month results and announces U.S. availability of a new ready-to-use immunoglobulin therapy for primary immunodeficiency, fueling discussions on its growth strategy amid high debt and margin pressures.
Travere Therapeutics faces a securities fraud investigation by Robbins Geller Rudman & Dowd LLP, raising questions about the accuracy of its past disclosures. The probe casts a shadow over the company's critical transition, as it banks on its kidney drug FILSPARI to drive growth amid mounting legal and commercial pressures.
Health and Human Services Secretary Robert F. Kennedy Jr. has publicly addressed the deep divisions within America's most storied political family, following the death of his cousin Tatiana Schlossberg and amidst ongoing policy controversies that have placed him at odds with his relatives.
As China's pork industry grapples with overcapacity and falling prices, a growing appetite for premium, flavorful black pork among the middle class is offering a lifeline to farmers and reshaping market strategies.
Investment firm Tanager Wealth Management has fully divested its position in Centessa Pharmaceuticals, capitalizing on the biotech's near-60% annual surge. The move highlights strategic portfolio rebalancing as the stock's rally potentially amplified its risk profile within a diversified fund.
